| Literature DB >> 9607857 |
S Heringlake1, J Ockenga, H L Tillmann, C Trautwein, D Meissner, M Stoll, J Hunt, C Jou, N Solomon, R E Schmidt, M P Manns.
Abstract
To investigate a possible influence of GB virus C (GBV-C) in immunocompromised patients, the prevalences of GBV-C RNA and anti-E2 antibody in 197 human immunodeficiency virus (HIV)-infected patients and in 120 control blood donors were studied. GBV-C RNA was detected in 33 of 197 HIV-infected patients (16.8%) compared with 1 in 120 blood donors (0.8%) (P < .001). Previous exposure to GBV-C (anti-E2 antibody-positive) was shown in 56.8% of HIV patients and in 9% of blood donors. GBV-C viremia was not associated with hepatitis. Despite approximately equal duration of HIV infection in all subgroups, the CD4 cell counts were significantly higher in GBV-C-viremic patients (344 cells/microL) compared with exposed (259 cells/microL) and unexposed (170 cells/microL) patients (P = .017 and P < .001). Furthermore, Kaplan-Meier analysis demonstrated significantly better cumulative survival in GBV-C RNA-positive HIV-infected patients, suggesting that GBV-C might be a favorable prognostic factor in HIV disease.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9607857 DOI： 10.1086/517431
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226